Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Capricor Therapeutics Inc.

www.capricor.com

Latest From Capricor Therapeutics Inc.

Deal Watch: Gilead And Spring Bank Set Second Trial Collaboration In HBV

Analyst speculates that Gilead could move to acquire Spring Bank if combo trial yields promising data for functional cure of hepatitis B. Eisai in-licenses PARP inhibitor with potential in breast cancer from Oncology Venture, while Sunovion out-licenses three corticosteroid products to Covis.

Deals Commercial

Without J&J, Capricor Plans To Advance Progenitor Cell Therapy In DMD

California biotech says it will move forward with knowledge and expertise gained through the failed partnership. Capricor hopes to re-partner CAP-1002 for cardiovascular indications, while continuing the candidate’s DMD development itself.

BioPharmaceutical Commercial

Pipeline Watch: Phase III Starts With Mogamulizumab, AR101 And Vilaprisan

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Pipeline Watch: Top-Line Lanadelumab, Inotersen, Durvalumab Results

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Capricor Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Capricor Therapeutics Inc.
  • Senior Management
  • Linda S Marban, PhD, Pres. & CEO
    Leland Gershell, MD, PhD, CFO
    Rachel Smith, PhD, VP, R&D
    Deborah Ascheim, MD, CMO
  • Contact Info
  • Capricor Therapeutics Inc.
    Phone: (310) 358-3200
    8840 Wilshire Blvd., 2nd Fl.
    Beverly Hills, CA 90211
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register